FDA sees suc­cess in mod­el-in­formed drug de­vel­op­ment pi­lot

Con­sult­ing the FDA on us­ing math­e­mat­i­cal sim­u­la­tions in drug de­vel­op­ment could make the process more ef­fi­cient, sav­ing spon­sors time and mon­ey, a re­port on the agency’s pi­lot pro­gram on mod­el-in­formed drug de­vel­op­ment con­clud­ed.

Four of­fi­cials in the Of­fice of Clin­i­cal Phar­ma­col­o­gy who led the pi­lot au­thored a re­port pub­lished Wednes­day on the agency’s Mod­el-In­formed Drug De­vel­op­ment (MIDD) pi­lot, a pro­gram spear­head­ed by the Cen­ter for Drug Eval­u­a­tion and Re­search that gave spon­sors ad­di­tion­al ac­cess to re­view­ers to get an­swers on how to use math­e­mat­i­cal mod­els in their drug tri­als. The pi­lot was es­tab­lished as part of the sixth it­er­a­tion of the Pre­scrip­tion Drug User Fee Act, which was im­ple­ment­ed in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER